Drug Trial Radar · NCT07199309
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 26, 2025
Primary completion
Jul 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Marea TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.
Conditions
- Hypertriglyceridemia
Interventions
MAR001Drug
Subcutaneous Injection
PlaceboDrug
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in TG area under the curve after a mixed mealTime frame: 12 weeks
- Change from baseline in peak plasma TG concentration after a mixed mealTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Marea Site 301
Chula Vista, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.